Research programme: WDR5 protein inhibitors - Alivexis
Alternative Names: MOD-DLatest Information Update: 16 Apr 2024
At a glance
- Originator Modulus Discovery
- Developer Alivexis
- Class Antineoplastics; Small molecules
- Mechanism of Action WDR5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Research Cancer
Most Recent Events
- 24 Aug 2023 WDR5 protein inhibitors - Modulus Discovery is available for licensing as of 24 Aug 2023. https://modulusdiscovery.com/pipeline/#partnering (Modulus Discovery pipeline, August 2023).
- 24 Aug 2023 Early research in Cancer in Japan (unspecified route) prior to August 2023 (Modulus Discovery pipeline, August 2023)